Critical drug interactions with agents used for prophylaxis and treatment of Mycobacterium avium complex infections

American Journal of Medicine

Volumn 102, Issue 5 C, 1997, Pages 32-36

  Benson, Constance A ^a  

^a RUSH MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CLARITHROMYCIN; CYTOCHROME P450; INDINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RIFABUTIN; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ANTIBIOTIC PROPHYLAXIS; AREA UNDER THE CURVE; ARTICLE; COMPETITIVE INHIBITION; DOSE KIDNEY FUNCTION RELATION; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG ELIMINATION; DRUG METABOLISM; ENZYME INHIBITION; MYCOBACTERIOSIS; PRIORITY JOURNAL;

EID: 0030818659     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0002-9343(97)00042-9     Document Type: Article

References (34)

1. Piscitelli SC, Flexner C, Minor JR, Polis MA, Masur H. Drug interactions in patients infected with human immunodeficiency virus. Clin Infect Dis. 23:1996;685-693.
2. Murray M. P-450 enzymes: inhibition mechanism, genetic regulation and effects of liver disease. Clin Pharmacokinet. 23:1992;132-146.
3. Smith DA, Jones BC. Speculations on the substrate structure-activity relationship (SSAR) of cytochrome P-450 enzymes. Biochem Pharmacol. 44:1992;2089-2098.
4. Benet LZ, Kroetz DL, Sheiner LB. Pharmacokinetics: the dynamics of drug absorption, distribution, and elimination. Hardman JG, Limbird LL. Goodman and Gilman's The Pharmacological Basis of Therapeutics. 9th ed. 96;3-27 McGraw-Hill, New York.
5. Norvir™ (Ritonavir) Package Insert/Product Monograph. North Chicago, IL: Abbott Laboratories, 1996.
6. Crixivan™ (Indinavir) Package Insert/Product Monograph. West Point, PA: Merck & Co., 1996.
7. Nizoral™ (Ketoconazole) Package Insert/Product Monograph. Titusville, NJ: Janssen Pharmaceutica, 1996.
8. Rifadin™ (Rifampin) Package Insert/Product Monograph. Kansas City, MO: Marion Merrell Dow, 1996.
9. Mycobutin™ (Rifabutin) Package Insert/Product Monograph. Kalamazoo, MI: Pharmacia & Upjohn, 1996.
10. Blum RA, D'Andrea DT, Florentino BM, et al. Increased gastric pH and the bioavailability of fluconazole and ketoconazole. Ann Intern Med. 114:1991;755-757.
11. Van Der Meer JWM, Keuning JJ, Scheijgrond HW, Heykants J, Van Cutsem J, Brugmans J. The influence of gastric acidity on the bio-availability of ketoconazole. J Antimicrob Chemother. 6:1980;552-554.
12. Moore KH, Yuen GJ, Raasch RH, et al. Pharmacokinetics of lamivudine administered alone and with trimethoprim-sulfamethoxazole. Clin Pharmacol Ther. 59:1996;550-558.
13. Honig PK, Wortham DC, Zamani K, Cantilena LR. Comparison of the effects of the macrolide antibiotics erythromycin, clarithromycin, and azithromycin on terfenadine steady-state pharmacokinetics and electrocardiographic parameters. Drug Investigations. 7:1994;148-154.
14. Propulsid™ (Cisapride) Package Insert/Product Monograph. Titusville, NJ: Janssen Pharmaceutica, 1996.
15. Biaxin™ (Clarithromycin) Package Insert/Product Monograph. North Chicago, IL: Abbott Laboratories, 1996.
16. DATRI 001 Study Group. Coadministration of clarithromycin alters the concentration-time profile of rifabutin. (Abstr. A2.) 34th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, 1994.
17. Wallace J Jr, Brown BA, Griffith DE, Girard W, Tanaka K. Reduced serum levels of clarithromycin in patients treated with multidrug regimens including rifampin or rifabutin for Mycobacterium avium-M. intracellulare infection. J Infect Dis. 171:1995;747-750.
18. Shafran SD, Deschenes J, Miller M, Phillips P, Toma E. Uveitis and pseudojaundice during a regimen of clarithromycin, rifabutin, and ethambutol. (Letter.). N Engl J Med. 330:1994;838-839.
19. Fuller JD, Stanfield LE, Craven DE. Rifabutin prophylaxis and uveitis. (Letter.). N Engl J Med. 330:1994;1315-1316.
20. Vincent J, Foulds G, Apseloff G, Laboy-Goral L, Gerber N. Interaction of rifabutin (RIF) with the macrolides azithromycin (AZM) and clarithromycin (CLA). (Abstr. A29.) 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, LA: 1996.
21. Smith JA, Hardin TC, Patterson TF, Rinaldi MG, Graybill JR. Rifabutin decreases itraconazole plasma levels in patients with HIV infection. (Abstr. 126.) 2nd National Conference on Human Retroviruses and Related Infections, Washington, DC, 1995.
22. Trapnell CB, Narang PK, Li R, Lavelle JP. Increased plasma rifabutin levels with concomitant fluconazole therapy in HIV-infected patients. Ann Intern Med. 124:1996;573-576.
23. Narang PK, Trapnell CB, Schoenfelder JR, Lavelle JP, Bianchine JR. Fluconazole and enhanced effect of rifabutin prophylaxis. (Letter.). N Engl J Med. 330:1994;1316-1317.
24. + patients. (Abstr. PI-49.) 97th Annual Meeting of the American Society of Clinical Pharmacology and Therapeutics, Orlando, FL, 1996.
25. Lee BL, Lampiris H, Colborn D, Lewis R, Narang PK, Sullam P. The effect of rifabutin (RBT) on the pharmacokinetics (PK) of trimethoprim-sulfamethoxazole (TMP-SMX) in HIV infected patients. (Abstr. A36.) 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, 1995.
26. Ouellet D, Hsu A, Granneman GR, et al. Assessment of the pharmacokinetic interaction between ritonavir and clarithromycin. (Abstr. PI-58.). Clin Pharmacol Ther. 59:1996;143.
27. Cato A, Cavanaugh JH, Shi H, Hsu A, Granneman GR, Leonard J. Assessment of multiple doses of ritonavir on the pharmacokinetics of rifabutin. (Abstr. Mo.B.1199.) 11th International Conference on AIDS, Vancouver, British Columbia, 1996.
28. Sun E, Heath-Chiozzi M, Cameron DW, et al. Concurrent ritonavir and rifabutin increases risk of rifabutin-associated adverse effects. (Abstr. Mo.B.171.) 11th International Conference on AIDS, Vancouver, British Columbia, 1996.
29. Indinavir Pharmacokinetic Study Group. Indinavir (MK 639) drug interaction studies. (Abstr. Mo.B.174.) 11th International Conference on AIDS, Vancouver, British Columbia, 1996.
30. Sahai J, Stewart F, Swick L, et al. Rifabutin (RBT) reduces saquinavir (SAQ) plasma levels in HIV-infected patients. (Abstr. A27.) 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, LA, 1996.
31. Invirase™ (Saquinavir) Package Insert/Product Monograph, Nutley, NJ: Hoffman-La Roche, 1996.
32. + patients. (Abstr. A48.) 34th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, 1994.
33. Viramune™ (Nevirapine) Package Insert/Product Monograph. Columbus, OH: Roxane Laboratories, 1996.
34. Gerber JG. Drug interaction issues in the treatment of HIV infection. HIV/AIDS Clinical Insight. 6:1996;1-6.